Haemophilia Heredity and Inheritance
How haemophilia is inherited: X-linked recessive inheritance, the role of carriers and probability of transmission.
The factor VIII gene
The gene for factor VIII is located on the X chromosome (locus Xq28), is 186,000 bp long (0.1% of the entire X chromosome), and contains 26 exons. The protein encoded by this gene is composed of 2,351 amino acids with a total relative mass of 267,039 daltons.
Inheritance of haemophilia
The location of the factor VIII gene on the gonosome (X chromosome) determines the recessive mode of inheritance of the disease. Women are very rarely affected, and most often have a carrier state, i.e. the presence of a single mutated allele that they can pass on to their offspring. Only boys are affected; rarely, a female with haemophilia may occur if her father had haemophilia and her mother was a carrier.
Practical implications
As a practical matter, it is essential that all the sons of a man with haemophilia will be healthy and all his daughters will be carriers. 50% of the sons of a carrier mother will be healthy and 50% will have haemophilia. Half of their daughters may also be carriers and half will be healthy women.
New mutations
About 20-30% of people with haemophilia have a negative family history. In this case, either the mutation is newly acquired or the condition has been passed down for generations only by female carriers, without clinical manifestations of the disease.
The manifestations of haemophilia, i.e. the extent of the condition, history and clinical course, as well as the factor level, are a direct expression of the genetic defect and tend to be the same in members of the same family. The disease occurs worldwide and no racial dependence has been found.
Haemophilia carriers
Haemophilia carriers are women who carry a mutated gene on one of their two X chromosomes. Although traditionally considered "healthy carriers", many carriers have reduced clotting factor levels (VIII or IX) and may experience increased bleeding — particularly heavier menstrual bleeding, postpartum haemorrhage, bleeding after surgery or dental procedures. Every carrier should have their clotting factor level measured and be under the care of a haematologist, especially when planning surgery or pregnancy.
Genetic testing and counselling
Modern genetic methods allow the identification of the specific mutation causing haemophilia in a family and subsequent targeted testing of other female family members for carrier status. Genetic counselling is a key component of care for families with haemophilia. Prenatal diagnosis (chorionic villus sampling or amniocentesis) can determine whether a foetus is affected by haemophilia as early as the first trimester of pregnancy. Genetic counselling at a haemophilia centre is recommended before a planned pregnancy.
Further information
- What is haemophilia
- Haemophilia treatment
- Von Willebrand disease — a related bleeding disorder
Related Articles

New Technologies in Treatment 2024
The first weekend of November is traditionally dedicated to a workshop on new technologies in treatment organized by the European Haemophilia Consortium (EHC).
Read more
Gene Therapy - A Practical Guide
We bring you a new publication—a translation of a practical guide on gene therapy published as part of the EHC’s editorial activities.
Read more
New Technologies in Treatment 2023
New developments in non-factor therapy, rebalancing therapy, gene therapy or artificial intelligence. These and other topics were discussed at the workshop on new technologies in the treatment of rare bleeding diseases, held in Lisbon, Portugal, November 3-5, 2023.
Read more
Advances in the Treatment of Hemophilia and von Willebrand Disease
From 11-13 November 2022, a workshop organized by the European Haemophilia Consortium took place in Marseille, France, focusing on new technologies in the treatment of hemophilia and other rare bleeding disorders. The Czech Hemophilia Society was represented on site by Vice-Chairman Martin Žídek and MUDr. Pavel Mazánek, who serves as Deputy Head of Haematology at the Department of Paediatric Haematology and Biochemistry at the University Hospital Brno.
Read more
Recommendations of the Czech National Hemophilia Program (CNHP) on Vaccination Against SARS-CoV-2
Recommendations on vaccination against SARS-CoV-2 (COVID-19) were published earlier this year in the journal Haemophilia, and a brief translation is available on our website at [this link](/novinky/prohlaseni-k-ockovani-proti-pandemii). The recommendations are endorsed by the World Federation of Hemophilia (WFH), the European Association for Haemophilia and Allied Disorders (EAHAD), the European Haemophilia Consortium (EHC), and the National Hemophilia Foundation of the United States (NHF). These recommendations, including their Czech translation, already contain all the essential information.
Read more
Statement on Pandemic Vaccination
Vaccination against COVID-19 is the most pressing topic of recent months. Statements have been issued by the World Federation of Hemophilia (WFH), the European Association for Haemophilia and Allied Disorders (EAHAD), the European Haemophilia Consortium (EHC), and the National Hemophilia Foundation of the United States (NHF). The statement applies to persons over 18 years of age; for younger individuals, we continue to monitor developments and studies.
Read more